Status:
COMPLETED
Serotonin-receptor Agonism in Reward Processing
Lead Sponsor:
University of Oxford
Conditions:
Anhedonia
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
There is growing animal and human evidence for role of 5HT1A receptor agonism in treating depression and reward deficits. The next step is to translate this evidence directly into humans by characteri...
Eligibility Criteria
Inclusion
- Participant is willing and able to give informed consent for participation in the research
- Male or female
- Body mass index in the range of 18 to 30
- Not currently taking any medications (except for contraception)
Exclusion
- • Any current Axis 1 The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) psychiatric disorder
- Any previous episode of a severe mental illness,
- A first degree relative diagnosed with Bipolar Affective Disorder Type 1 or Schizophrenia
- Body Mass Index outside the range of 18 to 30 inclusive
- Any significant current medical condition likely to interfere with conduct of the study or analysis of data (epilepsy, renal disease, hepatic disease, myasthenia gravis, acute closed-angle glaucoma)
- Current use of psychoactive and / or medically significant medication as judged by a study medic, whether prescribed or bought over the counter (the contraceptive pill, the Depo-Provera injection or the progesterone implant will not result in exclusion)
- Past history of dependence to illicit substances, and any consumption of illicit substances in the three months prior to the study
- Currently pregnant or breast feeding
- Known lactase deficiency or any other problem absorbing lactose, galactose, or glucose
- Participation in a study using the same tasks in the last year
- Any physical (including visual and auditory) or language impairment that would make complying with the study protocol challenging. This includes any taste/olfactory disturbance e.g. secondary to Covid-19 infection
Key Trial Info
Start Date :
May 13 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 18 2023
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT05357547
Start Date
May 13 2022
End Date
April 18 2023
Last Update
May 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurosciences building, Department of Psychiatry, Warneford hospital
Oxford, Oxfordshire, United Kingdom, OX3 7JX